Card image cap
DCGI approves Corbevax for 12-17 age group

The Drug Controller General of India (DCGI) has authorised vaccine-maker Biological E’s Corbevax for emergency use among children aged 12-17, making a third shot available in the Covid inoculation drive for youngsters. The Centre has already placed a purchase order for 5 crore doses of Corbevax, likely to be available in all the states by February-end. This is the third vaccine to be given an emergency use nod for 12-17 year-olds after Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCov-D.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment